Showing results (41-50 of 2,011) with videos related to
Sort By:
Pageof 202
British Journal of Rheumatology|July 1, 1995
Sleep intensity in fibromyalgia: focus on the microstructure of the sleep processA M Drewes, K D Nielsen, S J Taagholt, et al.British Journal of Rheumatology|July 1, 1995
Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosisO Kaye, E Palazzo, M Grossin, et al.British Journal of Rheumatology|July 1, 1995
Shared care between hospital and general practice: an audit of disease-modifying drug monitoring in rheumatoid arthritisP S Helliwell, M O'HaraBritish Journal of Rheumatology|January 1, 1993
Small bowel infarction in association with giant cell arteritisM J Phelan, K Kok, C Burrow, et al.British Journal of Rheumatology|May 1, 1996
Increased expression of the Ed-B-containing fibronectin (an embryonic isoform of fibronectin) in human osteoarthritic cartilageX Chevalier, N Groult, W HornebeckBritish Journal of Rheumatology|May 1, 1996
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritisH K Ronday, H H Smits, G N Van Muijen, et al.British Journal of Rheumatology|May 1, 1996
Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisoloneJ F Maillefert, M Maynadie, J G Tebib, et al.British Journal of Rheumatology|May 1, 1996
'Seronegative' Sjögren's syndrome manifested as a subset of chronic fatigue syndromeM Nishikai, K Akiya, T Tojo, et al.British Journal of Rheumatology|June 1, 1993
Excessive and dysregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implicationsI C Chikanza, P Petrou, G Chrousos, et al.British Journal of Rheumatology|June 1, 1993
The 'natural' history of active rheumatoid arthritis over 3-6 months--an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placeboD R Porter, H A CapellPageof 202